Drugs / Imipenem/cilastatin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01506271 Background | Jun 2012 → Aug 2014 | infectious peritonitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imipenem/cilastatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01506271 ↗ |
| Route | Intravenous | “A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.” NCT01506271 ↗ |